OCI Bio Investments

The firm invests in venture-stage biotechnology and life sciences companies. Its mandate covers therapeutics, diagnostics, medical devices, and digital health platforms, with a sourcing tilt toward innovation originating in Texas research institutions. The firm does not publish a detailed asset-allocation breakdown or stage-by-stage check-size range.

Deal flow likely originates through relationships with Texas biomedical research universities, hospital systems, and regional technology transfer offices. By operating away from coastal life science hubs, the firm can access university spinouts and early-stage therapeutic assets before they are broadly marketed to larger syndicates.

Yes. It operates as a private equity manager executing a venture capital strategy, focused exclusively on life sciences. It does not publicly identify as a family office or multi-strategy platform, and there is no indication of fund-of-funds or secondary-market activity.

The firm's investment activity is limited to biotechnology and healthcare. It does not participate in generalist software, consumer internet, fintech, or industrial technology rounds. This sector concentration reflects a specialized, rather than diversified, venture mandate.

No. OCI Bio Investments does not publish a portfolio list on a website or through regulatory filings that are readily accessible. The firm's private equity structure does not require the same public disclosures that registered investment advisers or publicly listed funds must provide.